SIRT2 and melanoma: Our previous study [49], the work of Wilking-Busch et al. [72] and this report demonstrate that SIRT2 in melanomas acts as a tumor promoter at least in the context of the tested drugs and is a promising candidate for new anti-melanoma targeted therapies.